Polymeric Nanoreactors as Emerging Nanoplatforms for Cancer Precise Nanomedicine

Li, Xin; Zhao, Xiaopeng; Lv, Runkai; Hao, Linhui; Huo, Fengwei; Yao, Xikuang

doi:10.1002/mabi.202000424

Cited by 9 publications

(8 citation statements)

References 135 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[9][10][11][12] These biosynthetic nanocompartments protect the encapsulated enzymes from their surroundings, leading to prolonged activity and less immunogenicity. [13][14][15] When appropriately selected, polymer-based compartments offer several advantages over liposomes, 16,17 such as enhanced mechanical and colloidal stability, 18 tuneable permeability 19 and stimuli responsiveness. 20,21 Enzyme biopharmaceuticals have been encapsulated in different types of nanocompartments in order to improve their properties, including stability against degradation or reduced toxicity.…”

Section: Introductionmentioning

confidence: 99%

Inverting glucuronidation of hymecromone in situ by catalytic nanocompartments

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Inverting glucuronidation of hymecromone in situ by catalytic nanocompartments

et al. 2022

View full text Add to dashboard Cite

show abstract

“…By utilization of these smart DDSs, Pt drugs are expected to be delivered precisely to the tumor site and released in tumor region with negligible accumulation in normal tissues and organs. [213,214] Therefore, maximized therapeutic efficacy and minimized sided effects of Pt drugs are envisioned in the future.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Platinum Drug‐Incorporating Polymeric Nanosystems for Precise Cancer Therapy

Liu

Wang

et al. 2023

Small

Self Cite

View full text Add to dashboard Cite

made great progress in the field of medicinal inorganic chemistry. [2] They have been extensively applied in various types of cancers such as bladder cancer, ovarian cancer, breast cancer, endometrial cancer, neck cancer, and lung cancer. [3] Generally, Pt-based anticancer drugs interact with gene nucleobases and cause DNA damage. For example, after cellular uptake, cisplatin will hydrolyze along with the dissociation of chloride ion, which is ascribed to relatively lower concentration of chloride ion in cytoplasm (4-10 mm) than that in blood (≈100 mm). The hydrolyzed cisplatin can further conjugate with N7 position of adenine (A) and guanine (G), distort the structure of DNA and inhibit G2/M transition of cell cycle, leading to cell apoptosis in the end. [4][5][6] However, Pt(II) analogue drugs face various side effects, such as vomiting, neurotoxicity, nephrotoxicity, ototoxity, and cardiotoxicity. [7] These severe side effects greatly limit their efficacy and have become huge obstacles for further clinical applications. Though great efforts have been devoted to improve the efficacy of Pt-based anticancer drugs. Up to now, there is no Pt(II)-based drug that fully solves the problems despite of years of research. [8,9] Meanwhile, drug resistance is another major challenge for Pt-based drugs. Further, the anticancer efficacy of these Pt(II)-based drugs is greatly compromised by the inactivation of intracellular coppertransporting proteins, such as glutathione (GSH) and metallothioneins (MT), through forming stable Pt(II)-S bond. Later, copper transporter ATP7A and ATP7B are involved in the efflux or translocation Pt(II)-S complex as well as multidrug resistance-associated protein MRP2. What's more, it is noteworthy that DNA damage caused by Pt lesions can be recovered by the nucleotide excision repair (NER) machinery, in which DNAadduct repair enzymes play the critical role, such as excision repair cross complementation 1. [10,11] To minimize side effects of Pt(II) drugs, Pt(IV) prodrug have drawn more and more attention for cancer therapy. [12][13][14][15][16] Compared to Pt(II) drugs, these Pt(IV) drugs have a six coordinate octahedral geometry with an inert d 6 electronic configuration. The two additional ligands can endow Pt(IV) prodrugs with additional lipophilicity, tumor targeting property, and enhanced cellular uptake. [17] After endocytosis, these Pt(IV) drugs can be reduced to active Pt(II) drugs by intracellular GSH, resulting in enhanced therapeutic efficacy and reduced side effects. [18] Ideally, Pt drugs should kill cancer cells exclusively without damaging the normal ones. However, the tumor selectivity of Platinum (Pt) drugs are widely used in clinic for cancer therapy, but their therapeutic outcomes are significantly compromised by severe side effects and acquired drug resistance. With the emerging immunotherapy and imaging-guided cancer therapy, precise delivery and release of Pt drugs have drawn great attention these days. The targeting delivery of Pt drugs can greatly increase the accumulation...

show abstract

“…[51] With indepth studies, PISA has become a hot research area in the field of polymer science, attracting a lot of attention. Recently, a series of excellent reviews summarized the progress of PISA from implement technique, [52][53][54][55][56][57] materials characteris tics, [44,[58][59][60][61][62][63][64][65][66] impact factors, [67][68][69][70][71][72][73][74] to application areas, [43,75,76] which highlight the advantages of PISA in fabricating polymerbased nanostructures. However, the important class of biomaterials is underrepresented yet as only few overviews about the generation of PBBNs via the PISA technique have been published.…”

Section: Introductionmentioning

confidence: 99%

Polymerization‐Induced Self‐Assembly: An Emerging Tool for Generating Polymer‐Based Biohybrid Nanostructures

Qiu

Han

Xing

et al. 2023

Small

View full text Add to dashboard Cite

The combination of biomolecules and synthetic polymers provides an easy access to utilize advantages from both the synthetic world and nature. This is not only important for the development of novel innovative materials, but also promotes the application of biomolecules in various fields including medicine, catalysis, and water treatment, etc. Due to the rapid progress in synthesis strategies for polymer nanomaterials and deepened understanding of biomolecules’ structures and functions, the construction of advanced polymer‐based biohybrid nanostructures (PBBNs) becomes prospective and attainable. Polymerization‐induced self‐assembly (PISA), as an efficient and versatile technique in obtaining polymeric nano‐objects at high concentrations, has demonstrated to be an attractive alternative to existing self‐assembly procedures. Those advantages induce the focus on the fabrication of PBBNs via the PISA technique. In this review, current preparation strategies are illustrated based on the PISA technique for achieving various PBBNs, including grafting‐from and grafting‐through methods, as well as encapsulation of biomolecules during and subsequent to the PISA process. Finally, advantages and drawbacks are discussed in the fabrication of PBBNs via the PISA technique and obstacles are identified that need to be overcome to enable commercial application.

show abstract

Polymeric Nanoreactors as Emerging Nanoplatforms for Cancer Precise Nanomedicine

Cited by 9 publications

References 135 publications

Inverting glucuronidation of hymecromone in situ by catalytic nanocompartments

Inverting glucuronidation of hymecromone in situ by catalytic nanocompartments

Platinum Drug‐Incorporating Polymeric Nanosystems for Precise Cancer Therapy

Polymerization‐Induced Self‐Assembly: An Emerging Tool for Generating Polymer‐Based Biohybrid Nanostructures

Contact Info

Product

Resources

About